FBXO7 Immunoreactivity in α-synuclein-containing inclusions in parkinson disease and multiple system atrophy

Journal of Neuropathology and Experimental Neurology

Volumn 72, Issue 6, 2013, Pages 482-488

  Zhao, Tianna ^a   Severijnen, Lies Anne ^a   Van Der Weiden, Marcel ^a   Zheng, Ping Pin ^a   Oostra, Ben A ^a   Hukema, Renate K ^a   Willemsen, Rob ^a   Kros, Johan M ^a   Bonifati, Vincenzo ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

FBXO7; Multiple system atrophy; Neuropathology; PARK15; Parkinson disease; Synucleinopathies Tauopathies

Indexed keywords

ALPHA SYNUCLEIN; F BOX ONLY PROTEIN 7; F BOX PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BRAIN CORTEX; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEWY BODY; LOCUS CERULEUS; OCCIPITAL CORTEX; PARIETAL CORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; PUTAMEN; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BRAIN; F-BOX PROTEINS; FEMALE; HEK293 CELLS; HUMANS; INCLUSION BODIES; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE;

EID: 84878636079     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e318293c586     Document Type: Article

References (16)

1. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:1044-53
2. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci 2003;991:1-14
3. Jankovic J. Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76
4. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: Refining the diagnostic criteria. Lancet Neurol 2009; 8:1150-57
5. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's diseaseYrelated pathology. Cell Tissue Res 2004;318:121-34
6. Tofaris GK, Spillantini MG. Alpha-synuclein dysfunction in Lewy body diseases. Mov Disord 2005;20(Suppl 12):S37-44
7. Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann NY Acad Sci 2000;920:16-27
8. Bonifati V. Genetics of parkinsonism. Parkinsonism Relat Disord 2007; 13(Suppl 3):S233-41
9. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 2011;91:1161-218
10. Shojaee S, Sina F, Banihosseini SS, et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500K SNP arrays. Am J Hum Genet 2008;82:1375-84
11. Di Fonzo A, Dekker MC, Montagna P, et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 2009;72:240-45
12. Zhao T, De Graaff E, Breedveld GJ, et al. Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15). PLoS One 2011;6:e16983
13. Zhao T, Zondervan-van der Linde H, Severijnen LA, et al. Dopaminergic neuronal loss and dopamine-dependent locomotor defects in fbxo7-deficient zebrafish. PLoS One 2012;7:e48911
14. Sharma S, Bandopadhyay R, Lashley T, et al. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: A morphological and quantitative study. Neuropathol Appl Neurobiol 2011;37:777-90
15. Gandhi S, Muqit MM, Stanyer L, et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 2006;129:1720-31
16. Vitte J, Traver S, De Paula A, et al. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol 2010;69:959-72